- Home
- ABUS
as 04-23-2025 4:00pm EST
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WARMINSTER |
| Market Cap: | 592.8M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.63 - $4.72 | Next Earning Date: | 05-05-2025 |
| Revenue: | $6,171,000 | Revenue Growth: | -65.98% |
| Revenue Growth (this year): | 14.57% | Revenue Growth (next year): | 15.84% |
Stock Insider Trading Activity of Arbutus Biopharma Corporation (ABUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Naftzger J. Christopher | ABUS | General Counsel and CCO | Feb 4 '25 | Sell | $3.28 | 11,333 | $37,206.24 | 86,244 | |
| Sims Karen | ABUS | Chief Medical Officer | Feb 4 '25 | Sell | $3.28 | 19,348 | $63,519.48 | 106,194 | |
| HASTINGS DAVID C | ABUS | Chief Financial Officer | Feb 4 '25 | Sell | $3.28 | 22,183 | $72,826.79 | 159,724 | |
| McElhaugh Michael J. | ABUS | Interim President & CEO | Feb 4 '25 | Sell | $3.28 | 23,790 | $78,102.57 | 1,481,003 |
Latest Arbutus Biopharma Corporation News
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 hours ago
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Zacks
23 days ago
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
Zacks
23 days ago
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
BioPharma Dive
a month ago
Novo gains Lexicon obesity drug; CRISPR COO to step down
Zacks
a month ago
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
a month ago
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Barrons.com
a month ago
As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious
MT Newswires
2 months ago
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement
Compare ABUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.